Article Text
PDF
Abstract
Background Neurointerventionists lack guidelines for the use of antithrombotic therapies in their clinical practice; consequently, there is likely to be significant heterogeneity in antithrombotic use between centers. Through a nationwide survey, we aimed to obtain an exhaustive cross-sectional overview of antithrombotic use in neurointerventional procedures in France.
Methods In April 2021, French neurointerventional surgery centers were invited to participate in a nationwide 51-question survey disseminated through an active trainee-led research collaborative network (the JENI-RC).
Results All 40 centers answered the survey. Fifty-one percent of centers reported using ticagrelor and 43% used clopidogrel as premedication before intracranial stenting. For flow diversion treatment, dual antiplatelet therapy was maintained for 3 or 6 months in 39% and 53% of centers, respectively, and aspirin was prescribed for 12 months or more than 12 months in 63% and 26% of centers, respectively. For unruptured aneurysms, the most common heparin bolus dose was 50 IU/kg (59%), and only 35% of centers monitored heparin activity for dose adjustment. Tirofiban was used in 64% of centers to treat thromboembolic complications. Fifteen percent of these comprehensive stroke centers reported using tenecteplase to treat acute ischemic strokes. Cangrelor appeared as an emergent drug in specific indications.
Conclusion This nationwide survey highlights the important heterogeneity in clinical practices across centers. There is a pressing need for trials and guidelines to further evaluate and harmonize antithrombotic regimens in the neurointerventional field.
- Drug
- Intervention
- Pharmacology
- Platelets
- Standards
Data availability statement
Data are available upon reasonable request.
Statistics from Altmetric.com
Data availability statement
Data are available upon reasonable request.
Footnotes
Twitter @jildazz, @gcharbonnier, @GuillaumeTess12, @dumasvictor2, @RaoulPop25, @CRISTIANMIHALEA, @gboulouis
Collaborators JENI Research Collaboration : Julien Boucherit, Gaultier Marnat, Mourad Cheddad El Aouni, Federico Bolognini, Pierre-Olivier Comby, Martin Bretzner, Riyad Hanafi, Maxime Drai, Benoit Testud, Cyril Dargazanli, Liang Liao, Wagih Ben Hassen, Julien Allard, François Delvoye, Pierre-François Manceau, Quentin Alias, Margaux Lefebvre, Dan Sorin Mihoc, Jean Darcourt, Kevin Janot, Vincent L'Allinec, Jean Papaxanthos and Vanessa Chalumeau. Other collaborators : Jacques Duranteau and Laurent Spelle.
Contributors JC, LA, and SF contributed to conception and design of the study. JC contributed to data collection and analysis and drafting the manuscript. SF, CLB, GB, and BK contributed to revising the manuscript for important intellectual content. All authors approved the final version to be published. JC is the guarantor of the overall content.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.